Trial
NCT06449482
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
—
Condition
Acute Myeloid Leukemia, Adult
Intervention
Selinexor
Why stopped
The number of participants in the study did not meet expectations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-30